$MRK News Article - Merck's KEYTRUDA (pembrolizum
Post# of 151
(Total Views: 310)
Posted On: 02/03/2023 8:30:44 AM
$MRK News Article - Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma https://marketwirenews.com/news-releases/merc...12794.html
(0)
(0)Merck & Co. Inc. (MRK) Stock Research Links
My Twitter: WhyteStocks
Scroll down for more posts ▼